Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-time Anti-Factor Xa Measurements for Enoxaparin Optimization
NCT02704052Phase 1Completed
- Sponsor
- University of Utah
- Start
- Mar 2016
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by University of Utah. Primary endpoint: Venous thromboembolism at 90 days. Started Mar 2016; status: completed.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02704052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02704052.